Janux Therapeutics

JANUX THERAPEUTICS INC

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Victorias Secre, Easton, OH

Mid Cap

News

Movers

Trading Ideas

ASAN

BTDR

FIVE

JANX

NBIS

NVCR

SOUN

VSCO

ZETA

Top performing mid-cap stocks last week: NBIS, SOUN, BTDR, ASAN, JANX, NVCR, KC, VSCO, ZETA, FIVE. Analysts raise price forecasts for these stocks.

SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?

bz_pharma_briefs

Analyst Color

Biotech

Health Care

Analyst Ratings

General

Janux Therapeutics reports updated clinical data for JANX007, highlighting significant efficacy, safety, and durability in advanced prostate cancer patients.

Janux Therapeutics&#39; Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst

ATT.AT&T

AAOI

AOSL

BBAI

CRDO

PRCH

UXIN

AT&amp;T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday

Janux Therapeutics Inc

Press Releases

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

Janux Therapeutics Announces Proposed Public Offering

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

Clear Street Launches Healthcare & Biotechnology Equity Research

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

CGEM

CRGX

DCTH

ELVN

ERAS

IMTX

IPSC

MLTX

NUVB

PTGX

YMAB

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Apogee Therapeutics

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Beam Therapeutics

Biohaven

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Denali Therapeutics

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Galapagos NV - American Depositary Shares

Galapagos

ImmunityBio

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Kymera Therapeutics

Mesoblast Limited - American Depositary Shares

Mesoblast

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MannKind

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vericel

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

HC Wainwright & Co.

Scotiabank

Cantor Fitzgerald

Stifel

Leerink Partners

Comments

Janux Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga